Prior efforts to image cholinergic projections in human brain in vivo had significant technical limitations. We used the vesicular acetylcholine transporter (VAChT) ligand [ F]fluoroethoxybenzovesamicol ([ F]FEOBV) and positron emission tomography to determine the regional distribution of VAChT binding sites in normal human brain. We studied 29 subjects (mean age 47 [range 20-81] years; 18 men; 11 women). [ F]FEOBV binding was highest in striatum, intermediate in the amygdala, hippocampal formation, thalamus, rostral brainstem, some cerebellar regions, and lower in other regions. Neocortical [ F]FEOBV binding was inhomogeneous with relatively high binding in insula, BA24, BA25, BA27, BA28, BA34, BA35, pericentral cortex, and lowest in BA17-19. Thalamic [ F]FEOBV binding was inhomogeneous with greatest binding in the lateral geniculate nuclei and relatively high binding in medial and posterior thalamus. Cerebellar cortical [ F]FEOBV binding was high in vermis and flocculus, and lower in the lateral cortices. Brainstem [ F]FEOBV binding was most prominent at the mesopontine junction, likely associated with the pedunculopontine-laterodorsal tegmental complex. Significant [ F]FEOBV binding was present throughout the brainstem. Some regions, including the striatum, primary sensorimotor cortex, and anterior cingulate cortex exhibited age-related decreases in [ F]FEOBV binding. These results are consistent with prior studies of cholinergic projections in other species and prior postmortem human studies. There is a distinctive pattern of human neocortical VChAT expression. The patterns of thalamic and cerebellar cortical cholinergic terminal distribution are likely unique to humans. Normal aging is associated with regionally specific reductions in [ F]FEOBV binding in some cortical regions and the striatum.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827569PMC
http://dx.doi.org/10.1002/cne.24541DOI Listing

Publication Analysis

Top Keywords

f]feobv binding
32
human brain
12
binding
12
f]feobv
9
vesicular acetylcholine
8
acetylcholine transporter
8
positron emission
8
emission tomography
8
cholinergic projections
8
binding inhomogeneous
8

Similar Publications

Background: Postural instability and gait disturbances (PIGD) represent a significant cause of disability in Parkinson's disease (PD). Cholinergic system dysfunction has been implicated in falls in PD. The occurrence of falls typically results in fear of falling (FoF) that in turn may lead to poorer balance self-efficacy.

View Article and Find Full Text PDF

Objective: Cognitive decline in Parkinson disease (PD) is a disabling and highly variable non-motor feature. While cholinergic systems degeneration is linked to cognitive impairments in PD, most prior research reported cross-sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ligand [ F]-fluoroethoxybenzovesamicol ([ F]-FEOBV) binding predicts longitudinal cognitive changes in mild to moderate, non-demented PD subjects.

View Article and Find Full Text PDF

Several therapeutics and biomarkers that target Alzheimer's disease (AD) are under development. Our clinical positron emission tomography (PET) research programs are interested in six radiopharmaceuticals to image patients with AD and related dementias, specifically [C]UCB-J and [F]SynVesT-1 for synaptic vesicle glycoprotein 2A as a marker of synaptic density, two vesicular acetylcholine transporter PET radiotracers: [F]FEOBV and [F]VAT, as well as the transmembrane AMPA receptor regulatory protein (TARP)-γ8 tracer, [F]JNJ-64511070, and the muscarinic acetylcholine receptor (mAChR) M4 tracer [C]MK-6884. The goal of this study was to compare all six radiotracers (labeled with tritium or F) by measuring their density variability in pathologically diagnosed cases of AD, mild cognitive impairment (MCI) and normal healthy volunteer (NHV) human brains, using thin-section autoradiography (ARG).

View Article and Find Full Text PDF

Introduction: [F]fluoroetoxybenzovesamicol ([F]FEOBV) is a positron emission topography (PET) tracer for the vesicular acetylcholine transporter (VAChT), a protein located predominantly in synaptic vesicles in cholinergic nerve terminals. We aimed to use [F]FEOBV PET to study the cholinergic topography of the healthy human brain.

Materials And Methods: [F]FEOBV PET brain data volumes of healthy elderly humans were normalized to standard space and intensity-normalized to the white matter.

View Article and Find Full Text PDF

Age-related neurodegenerative diseases have in common the occurrence of cognitive impairment, a highly incapacitating process that involves the cholinergic neurotransmission system. The vesicular acetylcholine transporter (VAChT) positron emission tomography (PET) tracer [F]fluoroethoxybenzovesamicol ((-)-[F]FEOBV) has recently demonstrated its high value to detect alterations of the cholinergic system in Alzheimer's disease, Parkinson's disease and dementia with Lewy body. We present here the development of the new vesamicol derivative tracer (-)-(R,R)-5-[F]fluorobenzovesamicol ((-)[F]FBVM) that we compared to (-)[F]FEOBV in the same experimental conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!